Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B

Su, Tung‐Hung; Hsu, Cary; Chen, Chi Ling; Liu, Chen–Hua; Huang, Yi‐Wen; Tseng, Tai Chung; Liu, Chun‐Jen; Chen, Pei‐Jer; Lai, Ming Yang; Chen, Ding‐Shinn

doi:10.3851/imp1696

Cited by 84 publications

(79 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies had demonstrated that serum HBsAg level could be used as a predictive marker of serum HBV DNA for patients infected with HBV (Su et al, 2010;Sun et al, 2012). As expected, our data show that serum HBV DNA, HBeAg, and HBsAg level could discriminate seminal HBV DNA-positive patients from seminal HBV DNA-negative patients.…”

Section: Discussionsupporting

confidence: 87%

Can hepatitis B virus DNA in semen be predicted by serum levels of hepatitis B virus DNA, HBeAg, and HBsAg in chronically infected men from infertile couples?

Fei

Yang

et al. 2015

Andrology

View full text Add to dashboard Cite

SUMMARYHepatitis B virus (HBV) in semen is important for father-to-child transmission of HBV and has adverse effects on sperm quality. However, risk factors associated with HBV in semen remain unclear. Serum HBV DNA and hepatitis B e antigen (HBeAg) levels may pose a risk on HBV in semen. This study aims to examine whether serum HBV DNA, HBeAg, and hepatitis B surface antigen (HBsAg) level were associated with HBV DNA in semen. 151 male patients chronically infected with HBV from infertile couples were included. Serum HBsAg and HBeAg were determined using an electrochemiluminescence immune assay (ECLIA). Serum and seminal plasma HBV DNA were detected by the QIAGEN Real-Time HBV DNA assay. Of 151 patients, 143 (94.7%) were serum HBV DNA-positive and 65 (43.0%) were seminal plasma HBV DNA-positive. Serum HBV DNA and HBeAg level of seminal plasma HBV DNA-positive patients were significantly higher (p < 0.001) as compared with those of seminal plasma HBV DNA-negative patients, HBsAg level of seminal plasma HBV DNA-positive patients was significantly lower (p < 0.001) compared with that of seminal plasma HBV DNA-negative patients. The best serum HBV DNA, HBeAg, and HBsAg value for discriminating between seminal plasma HBV DNA-positive and HBV DNA-negative patients were ≥6.9 log 10 IU/mL (sensitivity 100.0%, specificity 90.7%), >14.8 S/CO (sensitivity 96.9%, specificity 81.5%), and <1791.5 S/CO (sensitivity 81.5%, specificity 81.2%), respectively. The combination of serum HBV DNA and HBeAg had high diagnostic sensitivity (100.0%) and specificity (95.4%) for the presence of HBV DNA in semen. As such, these serum markers especially the combination of HBV DNA and HBeAg are useful predictors of the presence of HBV DNA in semen in HBV chronically infected men from infertile couples.

show abstract

Section: Discussionsupporting

confidence: 87%

Can hepatitis B virus DNA in semen be predicted by serum levels of hepatitis B virus DNA, HBeAg, and HBsAg in chronically infected men from infertile couples?

Fei

Yang

et al. 2015

Andrology

View full text Add to dashboard Cite

show abstract

“…More on-treatment decline of qHBsAg has been shown in patients with IFN-based therapy than in those with NUC therapy (Su et al 2010). Recent data further revealed the correlation between the declines of qHBsAg and HBV genotype in patients receiving IFN-based therapy .…”

Section: Interferon-based Therapymentioning

confidence: 99%

Hepatitis B Virus Genotypes and Variants

Lin

Kao

2015

Cold Spring Harbor Perspectives in Medicine

201

139

View full text Add to dashboard Cite

At least 10 hepatitis B virus (HBV) genotypes (A to J) with distinct geographic distributions and several HBV mutants, including precore/core promoter mutations and pre-S/S deletion mutations, have been recognized to be not only predictive of liver disease progression but also associated with response to antiviral therapy. HBV genotype -specific pathogenesis may contribute to heterogeneous clinical outcomes in chronic hepatitis B patients across the world. For example, patients with HBV genotypes C and D infection have a lower rate of spontaneous HBeAg seroconversion. In addition, HBV genotypes C and D have a higher frequency of core promoter and pre-S mutations than genotypes A and B. Genotypes C and D also carry a higher lifetime risk of cirrhosis and HCC development than genotypes A and B. Core promoter and pre-S mutations also correlate with an increased risk of hepatocellular carcinoma (HCC). Therapeutically, genotypes A and B patients have a better response to interferon-based therapy than genotypes C and D patients, but the response to nucleos(t)ide analogs is comparable across different HBV genotypes. In conclusion, HBV genotypes and variants may serve as viral genetic markers to predict disease progression as well as help practicing physicians optimize individualized antiviral therapy in clinical practice.

show abstract

“…HBsAg levels were quantified using the Architect HBsAg QT assay (Abbott Laboratories, Abbott Park, IL) according to the manufacturer's instructions. 12,19,20 The detection range of the Architect assay is 0.05-250 IU/mL; if the HBsAg level was found to be higher than 250 IU/mL, the samples were diluted to 1:100 to 1:1,000 to obtain a reading within the calibration curve range.…”

Section: Methodsmentioning

confidence: 99%

Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads

et al. 2012

Self Cite

View full text Add to dashboard Cite

Chronic hepatitis B patients with high viral loads are at increased risk of cirrhosis and hepatocellular carcinoma (HCC). In patients with low viral loads, higher hepatitis B surface antigen (HBsAg) levels have been shown to predict HCC development. However, little is known about the difference in risk for other hepatitis B virus (HBV)-related adverse outcomes with varying HBsAg levels. A total of 1,068 Taiwanese hepatitis B e antigen (HBeAg)-negative HBV carriers with serum HBV DNA level <2,000 IU/mL at baseline were followed for a mean duration of 13.0 years. Patients were categorized based on their HBsAg levels, and the relationships between HBsAg level and development of HBeAg-negative hepatitis, hepatitis flare, and cirrhosis were investigated. Of the 1068 patients with low viral loads, 280 developed HBeAg-negative hepatitis, with an annual incidence rate of 2.0%. HBsAg level, but not HBV DNA level, was found to be a risk factor for HBeAg-negative hepatitis. Multivariate analysis showed that the adjusted hazard ratio in patients with an HBsAg level !1,000 versus <1000 IU/mL was 1.5 (95% confidence interval, 1.2-1.9). The positive correlation was present when evaluating other endpoints, including hepatitis flare and cirrhosis, and remained consistent when the study population was restricted to those with normal alanine aminotransferase (ALT) level at baseline. The annual incidence rate of HBeAg-negative hepatitis was lowered to 1.1% in patients with low levels of HBV DNA, HBsAg, and ALT. Conclusion: In HBeAg-negative patients with low viral loads and genotype B or C virus infection, a higher HBsAg level can predict disease progression. HBsAg <1,000 IU/mL in combination with low levels of HBV DNA and ALT help define minimal-risk HBV carriers. (HEPATOLOGY 2013;57:441-450) H epatitis B virus (HBV) infection is a global health problem, resulting in more than 1 million deaths per year.1 Patients with chronic HBV infection are at risk of developing cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC), with an estimated lifetime risk of 25%-40% in carriers who acquire the virus early in life.

show abstract

Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B

Abstract: Serum HBsAg concentration might serve as a surrogate marker of HBV DNA level in CHB patients.

Cited by 84 publications

References 27 publications

Can hepatitis B virus DNA in semen be predicted by serum levels of hepatitis B virus DNA, HBeAg, and HBsAg in chronically infected men from infertile couples?

Can hepatitis B virus DNA in semen be predicted by serum levels of hepatitis B virus DNA, HBeAg, and HBsAg in chronically infected men from infertile couples?

Hepatitis B Virus Genotypes and Variants

Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads

Contact Info

Product

Resources

About